Buy Rating Affirmed for Plus Therapeutics Amid Strong Clinical Results and Positive Financial Outlook
Plus Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Maxim Group Maintains Plus Therapeutics(PSTV.US) With Buy Rating, Maintains Target Price $4
Buy Rating Affirmed for Plus Therapeutics on Strong Financials and Promising Clinical Trials
Express News | HC Wainwright & Co. Reiterates Buy on Plus Therapeutics, Maintains $8 Price Target
Plus Therapeutics Analyst Ratings
Buy Rating Affirmed for Plus Therapeutics Amidst Promising Clinical Trial Results
Q2 2024 Plus Therapeutics Inc Earnings Call
Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript Summary
Plus Therapeutics | 10-Q: Q2 2024 Earnings Report
Plus Therapeutics 2Q Loss/Shr 71c >PSTV
Plus Therapeutics 2Q Loss $2.94M >PSTV
Express News | Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Express News | Plus Therapeutics Q2 Net Income USD -2.94 Million
Express News | Plus Therapeutics Q2 Operating Expenses USD 4.976 Million
Express News | Plus Therapeutics Q2 Operating Income USD -3.697 Million
Express News | Plus Therapeutics Q2 Sales $1.28M Miss $1.68M Estimate
Plus Therapeutics Q2 24 Earnings Conference Call At 5:00 PM ET
Here's the Major Earnings After the Close Today
Plus Therapeutics Q2 2024 Earnings Preview
No Data